Trial reportPharmacological reports : PR2026
Topical latanoprost acid for female androgenetic alopecia: a pilot proof-of-concept trial with mechanistic evidence of prostaglandin F2α receptor activation.
Trial report in Pharmacological reports : PR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07412587 (Investigation of the Effect of Cosmetic Products Containing Latanoprost Acid on Hair Condition in Women Aged 18-60 Years), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Investigation of the Effect of Cosmetic Products Containing Latanoprost Acid on Hair Condition in Women Aged 18-60 Years
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundProstaglandin F2α receptor (FP receptor) signaling is a plausible target for promoting hair growth, but clinical data on topical latanoprost acid (the active free-acid FP agonist) in hair loss are lacking. This study aimed to evaluate the clinical efficacy, safety, and mechanistic basis of topical latanoprost acid in women with female androgenetic alopecia.
methodsIn this investigator-initiated, randomized, double-blind, single-center, dose-ranging pilot trial, 29 adult women with hair loss predominantly consistent with female androgenetic alopecia were randomized to vehicle (n = 2) or topical latanoprost acid 0.01% (n = 8), 0.05% (n = 13), or 0.1% (n = 6), applied once daily for 6 months. The primary endpoint was within-participant change in target-area hair count (TAHC, hairs/cm²) from baseline to month 6; trichoscopic activity markers (yellow dots) and follicular-unit (FU) remodeling were secondary and exploratory outcomes. Human hair dermal papilla cells (HHDPCs) were assessed for FP receptor-linked signaling (intracellular Ca²⁺ flux) and DNA synthesis by 5-ethynyl-2'-deoxyuridine (EdU) incorporation after exposure to latanoprost acid versus equimolar latanoprost.
resultsAn increase in TAHC was observed across all active treatment arms (mean ± SEM ΔTAHC: 17.8 ± 4.3, 23.5 ± 6.1, and 16.5 ± 6.5 hairs/cm² in the latanoprost acid 0.01%, 0.05%, and 0.1% arms, respectively). No significant between-arm differences were detected. Secondary and exploratory trichoscopic analyses showed reductions in yellow-dot counts, a decrease in single-hair FUs, and an increase in triple-hair FUs. Safety was favorable, with no serious adverse events. In mechanistic assays, latanoprost acid triggered rapid, concentration-dependent Ca²⁺ flux, whereas equimolar latanoprost produced delayed signals; neither compound altered EdU incorporation.
conclusionsIn this pilot proof-of-concept trial, topical latanoprost acid showed a coherent clinical-trichoscopic bioactivity signal, supported by FP receptor-linked signaling in HHDPCs. These findings require confirmation in larger randomized pharmacokinetic/pharmacodynamic-integrated trials designed to optimize dose, confirm efficacy, and further characterize long-term safety.
trial registrationClinicalTrials.gov, NCT07412587; registered on February 2, 2026.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.